[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-mountain-sickness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-mountain-sickness":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100405332","erythrocytapheresis-for-chronic-mountain-sickness-100405332",false,"NCT04557995","Erythrocytapheresis for Chronic Mountain Sickness","Efficacy and Safety of Erythrocytapheresis in Chronic Mountain Sickness: the ESCAPE-CMS Trial","Inclusion:\n\n1. Age ≥18 years;\n2. High-altitude residents or long-term dwellers (continuous residence at ≥2500 meters above sea level for at least 1 year), with no travel history to low-altitude areas in the past 3 months;\n3. Hemoglobin (Hb): Men: ≥210 g\u002FL, Women: ≥190 g\u002FL; at least one symptom or sign: headache, dizziness, dyspnea, palpitations, sleep disturbances, fatigue, localized cyanosis, burning sensation in palms\u002Fsoles, venous dilatation, muscle\u002Fjoint pain, loss of appetite, poor concentration, or memory changes; CMS total score ≥6;\n4. Written informed consent obtained from patients or their legal representatives.\n\nExclusion:\n\n1. Hematocrit \\\u003C 60%;\n2. Patients with erythrocytosis attributable to: polycythemia vera; secondary erythrocytosis due to dehydration, cyanotic congenital heart disease, or chronic obstructive pulmonary disease; or other underlying hematologic or oncologic conditions;\n3. Patients with active pneumonia, pulmonary embolism, or severe organ dysfunction (including cardiac, hepatic, or renal failure);\n4. Patients with contraindications to study procedures (including erythrocytapheresis, pulmonary function tests, or incremental shuttle walk test), such as impaired consciousness, pneumothorax, severe arrhythmia, or significant coagulation disorders;\n5. Patients who have received CMS-specific interventions within the last 6 months, including phlebotomy, erythrocytapheresis, or targeted pharmacotherapy;\n6. Patients currently pregnant, breastfeeding, or planning to become pregnant within 1 year;\n7. Any terminal condition with an estimated life expectancy of \\\u003C 6 months;\n8. Current participation in other clinical trials.","ALL","18 Years",{"count":19,"type":20},112,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study aims to explore the efficacy and safety of erythrocytapheresis in chronic mountain sickness",[26],"Chronic Mountain Sickness","RECRUITING","2026-03-29",{"date":30,"type":31},"2026-04-02","ACTUAL",{"date":33,"type":31},"2025-07-21",{"date":35,"type":20},"2029-10-01",{"name":37,"class":38},"Third Military Medical University","OTHER"]